Editas Medicine Inc
EDIT
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
146% downsideOvervalued by 146% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $265.31 Million |
|---|---|
| Enterprise Value | $203.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.8 |
| Beta | 2.1 |
| Outstanding Shares | 97,879,343 |
Return
| Return on Equity | -2471.73% |
|---|---|
| Return on Assets | -72.96% |
| Return on Invested Capital | 67.43% |
Valuation & Multiples
| P/E Ratio | -2.43 |
|---|---|
| PEG | 3.62 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.67 |
| Enterprise Value to EBIT | 2.75 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 14.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6882▲ 45.89% |
|---|---|
| Total Calls | 375,200▼ 62.56% |
| Total Puts | 258,200▲ 12.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.45%▲ 3.00% |
|---|---|
| Total Invested | $129.24M▲ 26.10% |
| Investors Holding | 212▲ 6.00% |
ESG Score
No data
About Editas Medicine Inc
CEO: Cynthia Collins Relevant Senate Committees
This powerful committee controls taxation (e.g., R&D tax credits, corporate tax rates), trade, and entitlement spending (e.g., Medicare pricing). These policies directly impact Editas Medicine's profitability, investment incentives, and future market access for its therapies.
Subcommittees within Appropriations determine precise cash flow for scientific research (e.g., NIH, NSF) and health programs, directly impacting the funding environment and potential grants available to Editas Medicine or its research partners.
This committee has direct oversight of the FDA and NIH. FDA approval is existential for biological products, and NIH funding is a major driver of fundamental and translational research in biotechnology, directly impacting Editas Medicine.
Intellectual property (patents) is absolutely critical for biotech companies like Editas, which rely on proprietary technologies like CRISPR. This committee's oversight of antitrust and IP law directly impacts Editas's core assets and market position.
Members receive classified briefings on global threats, including potential biological threats or pandemics, which can create significant informational asymmetry for biotech companies involved in related research or product development.